The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
about
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic reviewStarter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review.Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionHIV/AIDS epidemiology, pathogenesis, prevention, and treatmentCurrent perspectives in HIV post-exposure prophylaxis.Occupational exposure to HIV and the use of post-exposure prophylaxis.Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis.Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?Prevention of the sexual transmission of HIV-1: preparing for success.Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy.Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain.The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV.Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
P2860
Q26851448-E25CCE5A-CBCF-45F7-9D3D-1A4515FF40F5Q27691370-415A01FA-1D80-4C2C-8D95-77A3A4F675ACQ28481276-CBD70CCF-D793-4183-9AF2-A7CDD5D3A79FQ30356074-CF3F29B8-02FC-47E3-9C57-072F21B24BDAQ34434815-EB09DA59-4687-4907-84D8-D65BABC08602Q34656428-885F38D9-7944-4D30-8F40-6C96B7239228Q36205915-035B1EEE-707F-40FE-8030-B5622B76065BQ36597028-CEB62487-4F1D-4AB6-B236-082B8BC50FB1Q36813326-D8D29D93-D16D-4C4C-87E3-E01A2FE2F5F6Q36928539-E8306784-E347-4F30-8669-FF4CAD94EC4EQ36975282-6AFCFBB2-6AE3-4784-B3C2-1718A4D1B79BQ42107726-23C12EEE-9DF5-426A-B23A-A1B99DFAB04AQ42248762-593D905A-44E8-440A-88D7-F4210A1ABFDBQ42585462-DC56EDFC-9C91-4B2C-8F5A-81B9305C73A2Q44924502-130F5FF6-6BC4-4532-BD0B-B25C939743ACQ47830535-CE3BD84E-4A8B-4B2B-834A-78A9F55E03DE
P2860
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The use of a triple nucleoside ...... HIV post-exposure prophylaxis.
@en
The use of a triple nucleoside ...... HIV post-exposure prophylaxis.
@nl
type
label
The use of a triple nucleoside ...... HIV post-exposure prophylaxis.
@en
The use of a triple nucleoside ...... HIV post-exposure prophylaxis.
@nl
prefLabel
The use of a triple nucleoside ...... HIV post-exposure prophylaxis.
@en
The use of a triple nucleoside ...... HIV post-exposure prophylaxis.
@nl
P2093
P2860
P1433
P1476
The use of a triple nucleoside ...... HIV post-exposure prophylaxis.
@en
P2093
P2860
P304
P356
10.1111/J.1468-1293.2005.00288.X
P50
P577
2005-05-01T00:00:00Z